1 duplicate copy in the archive
Case Filed-28944House OversightIndustry overview of Curaleaf, CV Sciences, Elixinol, and Green Thumb Industries CBD product lines (Feb 2019)
November 11, 20252p5 persons
Case File
d-28944House OversightIndustry overview of Curaleaf, CV Sciences, Elixinol, and Green Thumb Industries CBD product lines (Feb 2019)
Financial Record
The passage provides a market‑focused summary of several publicly traded cannabis/MSO companies and their product expansions. It contains no specific allegations, financial flows, or connections to hi Curaleaf launched a CBD line sold in 47 states, targeting pharmacy chains and grocery stores. Curaleaf reported ~$45 M revenue for FY9M18 with 247% YoY growth and 57% gross margin. CV Sciences’ PlusC
Date
November 11, 2025
Source
House Oversight
Reference
House Oversight #024871
Pages
2
Persons
5
Integrity
No Hash Available
Loading document viewer...
Forum Discussions
This document was digitized, indexed, and cross-referenced with 1,500+ persons in the Epstein files. 100% free, ad-free, and independent.
Support This ProjectSupported by 1,550+ people worldwide
Annotations powered by Hypothesis. Select any text on this page to annotate or highlight it.